Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis August 11, 2022
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids August 9, 2022
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer July 12, 2022
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update May 18, 2022
Ceapro Inc. to Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids May 13, 2022
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization May 11, 2022
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights April 13, 2022
